The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Olch AJ. Soft-tissue tumors. Pediatric radiotherapy – planning and treatment. London: CRC Press, Taylor & Francis Group; 2013. p 241.
   Google Scholar
• Statens Serum Institut. Cancerregistret 2012. Available from: http://www.ssi.dk/Sundhedsdataogit/Registre/Cancerregisteret.aspx. [Cited 26 February 2014].
   Google Scholar
• Weiss S, Goldblum J. Prognostic factors. Enzinger & Weiss's soft tissue tumors, 5th ed. Maryland Heights: Mosby Elsevier; 2008. p 18–31.
   Google Scholar
• Reichardt P. High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 2002;41:157–67.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010;46:72–83.
   PubMed Web of Science ®Google Scholar
• Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol 2014;15:415–23.
   PubMed Web of Science ®Google Scholar
• Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M,Members of the Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 2008;34:339–47.
   PubMed Web of Science ®Google Scholar
• D’Incalci M, Badri N, Galmarini CM, Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer 2014;111: 646–50.
   PubMed Web of Science ®Google Scholar
• Dossi R, Frapolli R, Di Giandomenico S, Paracchini L, Bozzi F, Brich S, et al. Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer Epub 2014 Jun 10.
   Google Scholar
• Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27:4188–96.
   PubMed Web of Science ®Google Scholar
• Cesne AL, Judson I, Maki R, Grosso F, Schuetze S, Mehren MV, et al. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: A retrospective pooled analysis of five phase II trials. Br J Cancer 2013; 109:1717–24.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480–90.
   PubMed Web of Science ®Google Scholar
• Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 2012;23:771–6.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576–84.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Blessing JA, Street DG, Muller CY, Burke JJ, Hensley ML. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: A gynecologic oncology group study. Gynecol Oncol 2012;124:48–52.
   PubMed Web of Science ®Google Scholar
• Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890–9.
   PubMed Web of Science ®Google Scholar
• Mohan S, Gu S, Parikh A, Radhakrishnan J. Prevalence of hyponatremia and association with mortality: Results from NHANES. Am J Med 2013;126:1127–37.e1.
   PubMed Web of Science ®Google Scholar
• Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol 2014; 65:723–30.
   PubMed Web of Science ®Google Scholar
• Aggerholm-Pedersen N, Rasmussen P, Dybdahl H, Rossen P, Nielsen OS, Safwat A. Serum natrium determines outcome of treatment of advanced GIST with imatinib: A retrospective study of 80 patients from a single institution. ISRN Oncol 2011;2011:523915.
   PubMedGoogle Scholar
• Jeppesen AN, Jensen HK, Donskov F, Marcussen N, von der Maase H. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br J Cancer 2010;102:867–72.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. NCI Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0. 2009; Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010- 06-14_QuickReference_5x7.pdf. [Cited 26 February 2014].
   Google Scholar
• Ploner F, Lamm W, Schur S, Eisterer W, Kuhr T, Lindorfer A, et al. The Austrian experience with trabectedin in non- selected patients with metastatic soft tissue sarcoma (STS). J Cancer Res Clin Oncol 2013;139:1337–42.
   PubMed Web of Science ®Google Scholar
• Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: Results of a worldwide expanded access program study. Ann Oncol 2013;24:1703–9.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Abubaker K, Findlay J, Quinn M. Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance. J Cell Biochem 2013;114:21–34.
   PubMed Web of Science ®Google Scholar
• Izumiya M, Kabashima A, Higuchi H, Igarashi T, Sakai G, Iizuka H, et al. Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells. Anticancer Res 2012; 32:3847–53.
   PubMed Web of Science ®Google Scholar
• Reers S, Pfannerstill AC, Maushagen R, Pries R, Wollenberg B. Stem cell profiling in head and neck cancer reveals an Oct-4 expressing subpopulation with properties of chemoresistance. Oral Oncol 2014;50:155–62.
   PubMed Web of Science ®Google Scholar
• Chawla A, Sterns RH, Nigwekar SU, Cappuccio JD. Mortality and serum sodium: Do patients die from or with hyponatremia? Clin J Am Soc Nephrol 2011;6:960–5.
   PubMed Web of Science ®Google Scholar
• Szkandera J, Pichler M, Liegl-Atzwanger B, Absenger G, Stotz M, Ploner F, et al. The elevated pre-operative plasma fibrinogen level is an independent negative prognostic factor for cancer-specific, disease-free and overall survival in soft-tissue sarcoma patients. J Surg Oncol Epub 2013 Oct 7.
   Google Scholar
• Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Samonigg H, et al. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. Br J Cancer 2013;109:2316–22.
   PubMed Web of Science ®Google Scholar
• Szkandera J, Pichler M, Absenger G, Stotz M, Arminger F, Weissmueller M, et al. The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg 2014;208:210–4.
   PubMed Web of Science ®Google Scholar
• Szkandera J, Gerger A, Liegl-Atzwanger B, Absenger G, Stotz M, Friesenbichler J, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer 2014;135:362–70.
   PubMed Web of Science ®Google Scholar